Adma Biologics (ADMA) Other Non-Current Assets (2011 - 2025)

Adma Biologics has reported Other Non-Current Assets for 13 years, with the latest figure at $8.6 million in Q4 2025.

• For the quarter ending Q4 2025, Other Non-Current Assets rose 52.02% year-over-year to $8.6 million; the trailing twelve-month figure through Dec 2025 stood at $8.6 million (up 52.02% YoY), and the FY2025 full-year result was $8.6 million, up 52.02% from the prior year.
• Other Non-Current Assets for Q4 2025 stood at $8.6 million, down from $8.8 million in the prior quarter.
• The five-year high for Other Non-Current Assets was $9.1 million in Q2 2025, with the low at $2.2 million in Q1 2021.
• Historically, Other Non-Current Assets has averaged $5.4 million across 5 years, with a median of $5.0 million in 2022.
• The largest YoY upside for Other Non-Current Assets was 93.04% in 2021 against a maximum downside of 35.85% in 2021.
• Adma Biologics' Other Non-Current Assets stood at $4.1 million in 2021, then grew by 17.27% to $4.8 million in 2022, then declined by 2.1% to $4.7 million in 2023, then climbed by 21.13% to $5.7 million in 2024, then surged by 52.02% to $8.6 million in 2025.
• The last three Other Non-Current Assets figures came in at $8.6 million (Q4 2025), $8.8 million (Q3 2025), and $9.1 million (Q2 2025), per Business Quant data.